Vericel (NASDAQ:VCEL) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.
A number of other brokerages also recently weighed in on VCEL. ValuEngine upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BTIG Research set a $8.00 price target on shares of Vericel and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Piper Jaffray lifted their price target on shares of Vericel to $14.00 and gave the stock an “overweight” rating in a report on Monday, March 5th. Needham & Company LLC lifted their price target on shares of Vericel from $5.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 6th. Finally, Ladenburg Thalmann cut shares of Vericel from a “buy” rating to a “neutral” rating in a report on Tuesday, March 6th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $14.25.
Shares of NASDAQ VCEL opened at $11.93 on Friday. Vericel has a twelve month low of $2.35 and a twelve month high of $13.20. The company has a market capitalization of $437.27, a PE ratio of -23.85 and a beta of 3.18. The company has a current ratio of 3.86, a quick ratio of 3.57 and a debt-to-equity ratio of 0.75.
Vericel (NASDAQ:VCEL) last announced its earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. Vericel had a negative return on equity of 98.77% and a negative net margin of 27.04%. The firm had revenue of $23.35 million for the quarter. analysts forecast that Vericel will post -0.24 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new stake in shares of Vericel in the 4th quarter worth approximately $105,000. Bank of Montreal Can bought a new stake in shares of Vericel in the 4th quarter worth approximately $140,000. Wells Fargo & Company MN raised its holdings in shares of Vericel by 1,374.2% in the 4th quarter. Wells Fargo & Company MN now owns 30,029 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 27,992 shares during the period. Citadel Advisors LLC bought a new stake in shares of Vericel in the 3rd quarter worth approximately $235,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Vericel by 35.2% in the 4th quarter. Bank of New York Mellon Corp now owns 44,188 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 11,509 shares during the period. 36.91% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/04/13/vericel-vcel-stock-rating-upgraded-by-bidaskclub-2.html.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.